Feleke Rahel, Geda Biftu, Teji Roba Kedir, Weldegebreal Fitsum
Haramaya University, Hiwot Fana Specialized University Hospital, Harar, Ethiopia.
School of Nursing and Midwifery, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.
SAGE Open Med. 2020 Feb 10;8:2050312120906076. doi: 10.1177/2050312120906076. eCollection 2020.
Antiretroviral treatment failure occurred when the antiretroviral regimen is unable to control HIV infection. There is no information on antiretroviral therapy failure in this study area.
The aim of this study was to assess the magnitude and associated factors of antiretroviral therapy failure among HIV-positive adult patients in Harar public hospitals from January to February 2018.
An institution-based cross-sectional study was conducted using chart review data from February 2005 to July 2017. Systematic sampling technique was used to include a sample of 1094 patient charts. Data were analyzed by Statistical Package for Social Sciences version 20.0. Statistical significance was considered at < 0.05.
The prevalence of first-line antiretroviral treatment failure was 21% (95% confidence interval = 18.3-23.5). Being male in sex, age of 45-54 years, patients with World Health Organization stages 3 and 4 during antiretroviral therapy initiation, a baseline CD4 count <100 cells/mm, poor drug adherence, and on antiretroviral therapy follow-up for ⩾25 months were predictors of antiretroviral treatment failure.
In this study, the rate of antiretroviral treatment failure is relatively high. Therefore, the concerned body should pay attention to the predictors to reduce the risk of treatment failure among this study group.
当抗逆转录病毒治疗方案无法控制HIV感染时,即发生抗逆转录病毒治疗失败。本研究地区尚无关于抗逆转录病毒治疗失败的相关信息。
本研究旨在评估2018年1月至2月在哈勒尔公立医院的HIV阳性成年患者中抗逆转录病毒治疗失败的严重程度及相关因素。
采用基于机构的横断面研究,使用2005年2月至2017年7月的病历审查数据。采用系统抽样技术纳入1094份患者病历样本。数据采用社会科学统计软件包20.0进行分析。统计学显著性以<0.05为标准。
一线抗逆转录病毒治疗失败的患病率为21%(95%置信区间=18.3-23.5)。男性、年龄在45-54岁、开始抗逆转录病毒治疗时处于世界卫生组织3期和4期的患者、基线CD4细胞计数<100个/mm、药物依从性差以及接受抗逆转录病毒治疗随访≥25个月是抗逆转录病毒治疗失败的预测因素。
在本研究中,抗逆转录病毒治疗失败率相对较高。因此,相关机构应关注这些预测因素,以降低该研究组中治疗失败的风险。